A comprehensive view of Non-Vaccine Biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Regeneron announces formation of Regeneron Cell Medicines with the acquisition of 2seventy bio's full development and commercialization rights for novel immune cell therapies, along with discovery and clinical manufacturing capabilities

Monash University, Moderna create the Monash-Moderna Quantitative Pharmacology Accelerator, a five-year program to drive mRNA medicine advancements, including therapeutics and vaccines; Moderna invests $3.0M in the Australia-based partnership

FDA accepts Pfizer’s application for hemophilia B gene therapy fidanacogene elaparvovec; European Medicines Agency accepts Pfizer's marketing authorization application for the treatment

UPM Biomedicals reports clinical investigation has started for its FibDex nanocellulose wound dressing on superficial burns; FibDex, previously used for skin graft donor sites, is breathable, biocompatible, and promotes efficient wound healing

TriLink BioTechnologies to expand its mRNA manufacturing facility near San Diego, California, to meet demand from late-stage drug developers; new 32,000-square-foot facility to produce gene edited cell therapies, protein replacement therapies, vaccines

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count